The effects of DPP-IV inhibition in NOD mice with overt diabetes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F13%3A00058666" target="_blank" >RIV/00023001:_____/13:00058666 - isvavai.cz</a>

Výsledek na webu

<a href="http://fb.cuni.cz/file/5689/FB2013A0016.pdf" target="_blank" >http://fb.cuni.cz/file/5689/FB2013A0016.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The effects of DPP-IV inhibition in NOD mice with overt diabetes

Popis výsledku v původním jazyce

Sitagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor that exerts an anti-hyperglycaemic effect by preventing degradation of glucagon-like peptide 1 with subsequent beta-cell stimulation and potential regeneration. We tested whether sitagliptin therapy in symptomatic non-obese diabetic (NOD) mice would lead to changes in the immune cell profile, improve beta-cell survival and induce diabetes remission. Flow cytometry analysis of immune cells in the spleen and peripheral lymph nodes, immunohistology of the pancreas and DPP-IV activity were investigated in diabetic NOD mice, either treated or non-treated with sitagliptin, at 0, 7, 14 and 28 days after hyperglycaemia onset, and in non-diabetic NOD controls. While compared to diabetic controls sitagliptin prevented increase of the CD8(+)/CD4(+) ratio in pancreatic nodes after four weeks (0.443 +/- 0.067 vs. 0.544 +/- 0.131; P < 0.05), the population of Tregs in lymph nodes increased from day 0 to 28 in both treated and non-treated di

Název v anglickém jazyce

The effects of DPP-IV inhibition in NOD mice with overt diabetes

Popis výsledku anglicky

Sitagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor that exerts an anti-hyperglycaemic effect by preventing degradation of glucagon-like peptide 1 with subsequent beta-cell stimulation and potential regeneration. We tested whether sitagliptin therapy in symptomatic non-obese diabetic (NOD) mice would lead to changes in the immune cell profile, improve beta-cell survival and induce diabetes remission. Flow cytometry analysis of immune cells in the spleen and peripheral lymph nodes, immunohistology of the pancreas and DPP-IV activity were investigated in diabetic NOD mice, either treated or non-treated with sitagliptin, at 0, 7, 14 and 28 days after hyperglycaemia onset, and in non-diabetic NOD controls. While compared to diabetic controls sitagliptin prevented increase of the CD8(+)/CD4(+) ratio in pancreatic nodes after four weeks (0.443 +/- 0.067 vs. 0.544 +/- 0.131; P < 0.05), the population of Tregs in lymph nodes increased from day 0 to 28 in both treated and non-treated di

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

<a href="/cs/project/GAP304%2F10%2F0762" target="_blank" >GAP304/10/0762: Terapie diabetu 1. typu navozením imunologické tolerance a regenerace ?-buněk: preklinický model u NOD myší</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Folia biologica (Praha)

ISSN

0015-5500

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

116-122

Kód UT WoS článku

000322419900004

EID výsledku v databázi Scopus

—